المؤلفون: Trotman J., Rule S., Kloczko J., Tedeschi A., Buske C., Leblond V., Chan W.Y., Michel J., Schneider J., Tan Z., Cohen A., Huang J., Tam C.S., Opat S., Dimopoulos M., Sanz R.G., Lee H.-P., Trneny M., Varettoni M., D'Sa S., Owen R.G., Cull G., Mulligan S., Czyz J., Castillo J.J., Motta M., Siddiqi T., Mesa M.G., Gorrochategui M.G., Talaulikar D., Zinzani P.L., Askari E., Grosicki S., Oriol A.

مصطلحات الفهرس: pruritus/si [Side Effect], randomized controlled trial (topic), rash/si [Side Effect], respiratory tract infection/si [Side Effect], second cancer/si [Side Effect], skin cancer/si [Side Effect], splenomegaly, subdural hematoma/si [Side Effect], thrombocytopenia/si [Side Effect], upper respiratory tract infection/si [Side Effect], urinary tract infection/si [Side Effect], very elderly, Waldenstroem macroglobulinemia/dt [Drug Therapy], bendamustine/dt [Drug Therapy], chlorambucil/dt [Drug Therapy], cisplatin/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], dexamethasone/dt [Drug Therapy], enoxaparin/cb [Drug Combination], hemoglobin/ec [Endogenous Compound], hydrocortisone/dt [Drug Therapy], ifosfamide/dt [Drug Therapy], immunoglobulin M/ec [Endogenous Compound], lomustine/dt [Drug Therapy], melphalan/dt [Drug Therapy], methylprednisolone/dt [Drug Therapy], myeloid differentiation factor 88/ec [Endogenous Compound], ofatumumab/dt [Drug Therapy], prednisolone/dt [Drug Therapy], prednisone/dt [Drug Therapy], rituximab/dt [Drug Therapy], zanubrutinib/ae [Adverse Drug Reaction], zanubrutinib/cb [Drug Combination], zanubrutinib/dt [Drug Therapy], zanubrutinib/tm [Unexpected Outcome of Drug Treatment], MYD88 gene, zanubrutinib/pv [Special Situation for Pharmacovigilance], adult, aged, anemia/si [Side Effect], arthralgia/si [Side Effect], article, atrial fibrillation/si [Side Effect], backache/si [Side Effect], basal cell carcinoma/si [Side Effect], bleeding/si [Side Effect], cellulitis/si [Side Effect], clinical article, constipation/si [Side Effect], contusion/si [Side Effect], coughing/si [Side Effect], decreased appetite/si [Side Effect], diarrhea/si [Side Effect], drug dose reduction, drug efficacy, drug safety, drug withdrawal, fatigue/si [Side Effect], female, fever/si [Side Effect], gene mutation, headache/si [Side Effect], hemoptysis/si [Side Effect], herpes zoster/si [Side Effect], human, hypertension/si [Side Effect], hyponatremia/si [Side Effect], infection/si [Side Effect], laceration/si [Side Effect], lymphadenopathy, male, monotherapy, multicenter study (topic), muscle spasm/si [Side Effect], neutropenia/si [Side Effect], opportunistic infection/si [Side Effect], overall survival, peripheral edema/si [Side Effect], phase 3 clinical trial (topic), pneumonia/si [Side Effect], priority journal, progression free survival, Article

URL: Click here for full text options
LibKey Link

المؤلفون: Trotman J., Rule S., Kloczko J., Tedeschi A., Buske C., Leblond V., Chan W.Y., Michel J., Schneider J., Tan Z., Cohen A., Huang J., Tam C.S., Opat S., Dimopoulos M., Sanz R.G., Lee H.-P., Trneny M., Varettoni M., D'Sa S., Owen R.G., Cull G., Mulligan S., Czyz J., Castillo J.J., Motta M., Siddiqi T., Mesa M.G., Gorrochategui M.G., Talaulikar D., Zinzani P.L., Askari E., Grosicki S., Oriol A.

مصطلحات الفهرس: pruritus/si [Side Effect], randomized controlled trial (topic), rash/si [Side Effect], respiratory tract infection/si [Side Effect], second cancer/si [Side Effect], skin cancer/si [Side Effect], splenomegaly, subdural hematoma/si [Side Effect], thrombocytopenia/si [Side Effect], upper respiratory tract infection/si [Side Effect], urinary tract infection/si [Side Effect], very elderly, Waldenstroem macroglobulinemia/dt [Drug Therapy], bendamustine/dt [Drug Therapy], chlorambucil/dt [Drug Therapy], cisplatin/dt [Drug Therapy], cyclophosphamide/dt [Drug Therapy], dexamethasone/dt [Drug Therapy], enoxaparin/cb [Drug Combination], hemoglobin/ec [Endogenous Compound], hydrocortisone/dt [Drug Therapy], ifosfamide/dt [Drug Therapy], immunoglobulin M/ec [Endogenous Compound], lomustine/dt [Drug Therapy], melphalan/dt [Drug Therapy], methylprednisolone/dt [Drug Therapy], myeloid differentiation factor 88/ec [Endogenous Compound], ofatumumab/dt [Drug Therapy], prednisolone/dt [Drug Therapy], prednisone/dt [Drug Therapy], rituximab/dt [Drug Therapy], zanubrutinib/ae [Adverse Drug Reaction], zanubrutinib/cb [Drug Combination], zanubrutinib/dt [Drug Therapy], zanubrutinib/tm [Unexpected Outcome of Drug Treatment], MYD88 gene, zanubrutinib/pv [Special Situation for Pharmacovigilance], adult, aged, anemia/si [Side Effect], arthralgia/si [Side Effect], article, atrial fibrillation/si [Side Effect], backache/si [Side Effect], basal cell carcinoma/si [Side Effect], bleeding/si [Side Effect], cellulitis/si [Side Effect], clinical article, constipation/si [Side Effect], contusion/si [Side Effect], coughing/si [Side Effect], decreased appetite/si [Side Effect], diarrhea/si [Side Effect], drug dose reduction, drug efficacy, drug safety, drug withdrawal, fatigue/si [Side Effect], female, fever/si [Side Effect], gene mutation, headache/si [Side Effect], hemoptysis/si [Side Effect], herpes zoster/si [Side Effect], human, hypertension/si [Side Effect], hyponatremia/si [Side Effect], infection/si [Side Effect], laceration/si [Side Effect], lymphadenopathy, male, monotherapy, multicenter study (topic), muscle spasm/si [Side Effect], neutropenia/si [Side Effect], opportunistic infection/si [Side Effect], overall survival, peripheral edema/si [Side Effect], phase 3 clinical trial (topic), pneumonia/si [Side Effect], priority journal, progression free survival, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28760
Blood Advances
LibKey Link

المؤلفون: Yuen M.-F., Agarwal K., Gane E.J., Schwabe C., Ahn S.H., Kim D.J., Lim Y.-S., Cheng W., Sievert W., Visvanathan K., Ruby E., Liaw S., Yan R., Huang Q., Colonno R., Lopatin U.

مصطلحات الفهرس: drug dose reduction, drug efficacy, drug elimination, drug half life, drug safety, drug tolerability, drug withdrawal, dry throat/si [Side Effect], eczema/si [Side Effect], epistaxis/si [Side Effect], faintness/si [Side Effect], fasting, fatigue/si [Side Effect], female, flu like syndrome/si [Side Effect], gastroenteritis/si [Side Effect], gastroesophageal reflux/si [Side Effect], gingiva pain/si [Side Effect], headache/si [Side Effect], heart palpitation/si [Side Effect], hematoma/si [Side Effect], hepatitis B/dt [Drug Therapy], hepatitis B/si [Side Effect], human, hypertension/si [Side Effect], increased appetite/si [Side Effect], injection site reaction/si [Side Effect], insomnia/si [Side Effect], maculopapular rash/si [Side Effect], male, maximum plasma concentration, mental instability/si [Side Effect], mouth ulcer/si [Side Effect], multiple drug dose, musculoskeletal pain/si [Side Effect], mycosis/si [Side Effect], nausea/si [Side Effect], neck pain/si [Side Effect], nose obstruction/si [Side Effect], oropharynx pain/si [Side Effect], pain/si [Side Effect], petechia/si [Side Effect], pharmacokinetics, phase 1 clinical trial, photosensitivity/si [Side Effect], pigmented nevus/si [Side Effect], positional dizziness/si [Side Effect], priority journal, pruritus/si [Side Effect], randomized controlled trial, rash/si [Side Effect], real time polymerase chain reaction, rhinorrhea/si [Side Effect], single drug dose, skin bruising/si [Side Effect], skin irritation/si [Side Effect], skin manifestation/si [Side Effect], sprain/si [Side Effect], sunburn/si [Side Effect], sweat gland disease/si [Side Effect], thorax pain/si [Side Effect], time to maximum plasma concentration, tonsillitis/si [Side Effect], treatment response, upper abdominal pain/si [Side Effect], virus load, volume of distribution, vomiting/si [Side Effect], wound/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], hepatitis B core antibody/ae [Adverse Drug Reaction], hepatitis B core antibody/ct [Clinical Trial], hepatitis B core antibody/cm [Drug Comparison], hepatitis B core antibody/cr [Drug Concentration], hepatitis B core antibody/do [Drug Dose], hepatitis B core antibody/dt [Drug Therapy], hepatitis B core antibody/po [Oral Drug Administration], hepatitis B core antibody/pk [Pharmacokinetics], hepatitis B core antigen, hepatitis B surface antigen, hepatitis B(e) antigen, placebo, virus DNA, virus RNA, dysgeusia/si [Side Effect], presyncope/si [Side Effect], abdominal discomfort/si [Side Effect], abdominal distension/si [Side Effect], abdominal pain/si [Side Effect], adult, allergy/si [Side Effect], antiviral activity, area under the curve, article, asthenopia/si [Side Effect], backache/si [Side Effect], catheter infection/si [Side Effect], chronic hepatitis B/dt [Drug Therapy], chronic hepatitis B/si [Side Effect], clinical article, cohort analysis, conjunctivitis/si [Side Effect], constipation/si [Side Effect], controlled study, coughing/si [Side Effect], crackle/si [Side Effect], decreased appetite/si [Side Effect], dehydration/si [Side Effect], diarrhea/si [Side Effect], dizziness/si [Side Effect], drug dose comparison, drug dose increase, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29395
Click here for full text options
LibKey Link

المؤلفون: Burge M., Segelov E., Tebbutt N.C., Reece W.H.H., Price T., Molloy M.P., Marx G., Jones K., Gibbs P., Feeney K., Clarke S.J.

مصطلحات الفهرس: intestine fistula/si [Side Effect], intestine perforation/si [Side Effect], large intestine perforation/si [Side Effect], lung embolism/si [Side Effect], major clinical study, male, metastatic colorectal cancer/dt [Drug Therapy], mucosa inflammation/si [Side Effect], multicenter study, multiple cycle treatment, nausea/si [Side Effect], neutropenia/si [Side Effect], neutrophil lymphocyte ratio, open study, overall survival, paresthesia/si [Side Effect], perianal abscess/si [Side Effect], peripheral neuropathy/si [Side Effect], phase 4 clinical trial, progression free survival, proteinuria/si [Side Effect], proteomics, rectum perforation/si [Side Effect], survival rate, treatment outcome, vomiting/si [Side Effect], bevacizumab/ae [Adverse Drug Reaction], bevacizumab/ct [Clinical Trial], bevacizumab/dt [Drug Therapy], capecitabine plus oxaliplatin/ct [Clinical Trial], capecitabine plus oxaliplatin/dt [Drug Therapy], proteome/ec [Endogenous Compound], capecitabine plus oxaliplatin/ae [Adverse Drug Reaction], abdominal pain/si [Side Effect], adult, aged, alopecia/si [Side Effect], anus fistula/si [Side Effect], article, cancer combination chemotherapy, cancer prognosis, carcinoma in situ/dt [Drug Therapy], constipation/si [Side Effect], controlled study, decreased appetite/si [Side Effect], diarrhea/si [Side Effect], digestive system perforation/si [Side Effect], drug safety, epistaxis/si [Side Effect], exploratory research, fatigue/si [Side Effect], female, gastroesophageal reflux/si [Side Effect], hand foot syndrome/si [Side Effect], human, hypertension/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29334
PLoS ONE
Click here for full text options
LibKey Link

المؤلفون: Atkinson V., Haydon A., Millward M., Begbie S., Brown M., Markman B., Patterson W., Hill A., Horvath L., Nagrial A., Richardson G., Jackson C., Friedlander M., Parente P., Tran B., Wang L., Chen Y., Tang Z., Huang W., Wu J., Zeng D., Luo L., Solomon B., Desai J., Gan H., Barrow C., Jameson M.

مصطلحات الفهرس: endometrium cancer/di [Diagnosis], endometrium cancer/dt [Drug Therapy], endometrium cancer/et [Etiology], enzyme inhibition, fatigue/si [Side Effect], female, fever/si [Side Effect], gastroesophageal reflux/si [Side Effect], glossodynia/si [Side Effect], hand foot syndrome/si [Side Effect], headache/si [Side Effect], human, hyperkeratosis/si [Side Effect], hypertension/si [Side Effect], hypomagnesemia/si [Side Effect], hypophosphatemia/si [Side Effect], hypotension/si [Side Effect], insomnia/si [Side Effect], intestine obstruction/si [Side Effect], intestine perforation/si [Side Effect], lethargy/si [Side Effect], limb pain/si [Side Effect], major clinical study, male, maximum plasma concentration, maximum tolerated dose, melanoma/di [Diagnosis], melanoma/dt [Drug Therapy], melanoma/et [Etiology], multiple cycle treatment, muscle spasm/si [Side Effect], musculoskeletal chest pain/si [Side Effect], myalgia/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], non small cell lung cancer/di [Diagnosis], non small cell lung cancer/dt [Drug Therapy], non small cell lung cancer/et [Etiology], oncogene N ras, oropharynx pain/si [Side Effect], ovary cancer/di [Diagnosis], ovary cancer/dt [Drug Therapy], ovary cancer/et [Etiology], palmoplantar keratoderma/si [Side Effect], pericardial effusion/si [Side Effect], phase 1 clinical trial, photosensitivity/si [Side Effect], pleura effusion/si [Side Effect], positron emission tomography-computed tomography, priority journal, progression free survival, pruritus/si [Side Effect], QT prolongation/si [Side Effect], rash/si [Side Effect], sepsis/si [Side Effect], side effect/si [Side Effect], skin defect/si [Side Effect], skin hypertrophy/si [Side Effect], solid malignant neoplasm, thrombocytopenia/si [Side Effect], thrush/si [Side Effect], thyroid cancer/di [Diagnosis], thyroid cancer/dt [Drug Therapy], thyroid cancer/et [Etiology], thyroid papillary carcinoma/di [Diagnosis], thyroid papillary carcinoma/dt [Drug Therapy], thyroid papillary carcinoma/et [Etiology], treatment duration, upper abdominal pain/si [Side Effect], upper respiratory tract infection/si [Side Effect], urinary tract infection/si [Side Effect], vomiting/si [Side Effect], xerostomia/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], B Raf kinase/ec [Endogenous Compound], K ras protein/ec [Endogenous Compound], lifirafenib/ae [Adverse Drug Reaction], lifirafenib/ct [Clinical Trial], lifirafenib/cr [Drug Concentration], lifirafenib/do [Drug Dose], lifirafenib/dt [Drug Therapy], lifirafenib/to [Drug Toxicity], lifirafenib/pd [Pharmacology], dizziness/si [Side Effect], abdominal pain/si [Side Effect], adult, aged, alanine aminotransferase blood level, anemia/si [Side Effect], antineoplastic activity, arthralgia/si [Side Effect], article, backache/si [Side Effect], blood level, blood toxicity/si [Side Effect], body weight disorder/si [Side Effect], body weight loss, brain hemorrhage/si [Side Effect], cancer chemotherapy, cancer patient, cancer radiotherapy, cancer staging, cancer survival, chill/si [Side Effect], cohort analysis, colorectal cancer/di [Diagnosis], colorectal cancer/dt [Drug Therapy], colorectal cancer/et [Etiology], constipation/si [Side Effect], coughing/si [Side Effect], decreased appetite/si [Side Effect], dermatitis/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation/si [Side Effect], drug blood level, drug dose increase, drug half life, drug safety, drug tolerability, dry skin/si [Side Effect], dysgeusia/si [Side Effect], dysphonia/si [Side Effect], dyspnea/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28975
Journal of Clinical Oncology
Click here for full text options
LibKey Link

المؤلفون: Freeman J.L., Legge D., Huque M.H., Anderson M., Gillam L., Ong K.S., Carlin J.B., Fahey M., Scheffer I.E., Cranswick N., Slota-Kan S., Lilley B., Dirnbauer N.

مصطلحات الفهرس: anticonvulsive agent/dt [Drug Therapy], randomized controlled trial, cannabidiol/ct [Clinical Trial], cannabidiol/ae [Adverse Drug Reaction], anticonvulsive agent/pv [Special Situation for Pharmacovigilance], add on therapy, article, Bayes theorem, clinical decision making, clinical practice, clinical protocol, controlled study, convulsion/si [Side Effect], decreased appetite/si [Side Effect], diarrhea/si [Side Effect], double blind procedure, drug dose regimen, drug dose titration, drug efficacy, fatigue/si [Side Effect], fever/si [Side Effect], gastrointestinal symptom/si [Side Effect], human, intractable epilepsy/dt [Drug Therapy], intractable epilepsy/pc [Prevention], lethargy/si [Side Effect], outcome assessment, outpatient department, patient compliance, priority journal, cannabidiol/cb [Drug Combination], cannabidiol/cm [Drug Comparison], cannabidiol/do [Drug Dose], cannabidiol/dt [Drug Therapy], cannabidiol/po [Oral Drug Administration], cannabidiol/pv [Special Situation for Pharmacovigilance], placebo, valproic acid/ae [Adverse Drug Reaction], valproic acid/cb [Drug Combination], valproic acid/dt [Drug Therapy], valproic acid/pv [Special Situation for Pharmacovigilance], anticonvulsive agent/cb [Drug Combination], aminotransferase/ec [Endogenous Compound], vomiting/si [Side Effect], treatment planning, somnolence/si [Side Effect], side effect/si [Side Effect], Article

URL: Journal of Paediatrics and Child Health
Click here for full text options
LibKey Link

المؤلفون: Qi Q., Chao Y., Hill A., Kang J., Wang L., Li K., Gan H., Wu Z., Yen C.-J., Markman B.

مصطلحات الفهرس: response evaluation criteria in solid tumors, treatment outcome, treatment response, upper respiratory tract infection/si [Side Effect], sorafenib/ae [Adverse Drug Reaction], sorafenib/ct [Clinical Trial], sorafenib/dt [Drug Therapy], tislelizumab/ae [Adverse Drug Reaction], tislelizumab/ct [Clinical Trial], tislelizumab/do [Drug Dose], tislelizumab/dt [Drug Therapy], human, advanced cancer/dt [Drug Therapy], antineoplastic activity, article, ascites/si [Side Effect], cancer control, clinical article, coughing/si [Side Effect], decreased appetite/si [Side Effect], drug dose escalation, drug eruption/si [Side Effect], drug fatality/si [Side Effect], drug safety, drug tolerability, fatigue/si [Side Effect], fever/si [Side Effect], liver cell carcinoma/dt [Drug Therapy], multicenter study, open study, phase 1 clinical trial, priority journal, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38361
Annals of Oncology
Click here for full text options
LibKey Link

المؤلفون: Yuen M.-F., Agarwal K., Gane E.J., Schwabe C., Ahn S.H., Kim D.J., Lim Y.-S., Cheng W., Sievert W., Visvanathan K., Ruby E., Liaw S., Yan R., Huang Q., Colonno R., Lopatin U.

مصطلحات الفهرس: drug dose reduction, drug efficacy, drug elimination, drug half life, drug safety, drug tolerability, drug withdrawal, dry throat/si [Side Effect], eczema/si [Side Effect], epistaxis/si [Side Effect], faintness/si [Side Effect], fasting, fatigue/si [Side Effect], female, flu like syndrome/si [Side Effect], gastroenteritis/si [Side Effect], gastroesophageal reflux/si [Side Effect], gingiva pain/si [Side Effect], headache/si [Side Effect], heart palpitation/si [Side Effect], hematoma/si [Side Effect], hepatitis B/dt [Drug Therapy], hepatitis B/si [Side Effect], human, hypertension/si [Side Effect], increased appetite/si [Side Effect], injection site reaction/si [Side Effect], insomnia/si [Side Effect], maculopapular rash/si [Side Effect], male, maximum plasma concentration, mental instability/si [Side Effect], mouth ulcer/si [Side Effect], multiple drug dose, musculoskeletal pain/si [Side Effect], mycosis/si [Side Effect], nausea/si [Side Effect], neck pain/si [Side Effect], nose obstruction/si [Side Effect], oropharynx pain/si [Side Effect], pain/si [Side Effect], petechia/si [Side Effect], pharmacokinetics, phase 1 clinical trial, photosensitivity/si [Side Effect], pigmented nevus/si [Side Effect], positional dizziness/si [Side Effect], priority journal, pruritus/si [Side Effect], randomized controlled trial, rash/si [Side Effect], real time polymerase chain reaction, rhinorrhea/si [Side Effect], single drug dose, skin bruising/si [Side Effect], skin irritation/si [Side Effect], skin manifestation/si [Side Effect], sprain/si [Side Effect], sunburn/si [Side Effect], sweat gland disease/si [Side Effect], thorax pain/si [Side Effect], time to maximum plasma concentration, tonsillitis/si [Side Effect], treatment response, upper abdominal pain/si [Side Effect], virus load, volume of distribution, vomiting/si [Side Effect], wound/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], hepatitis B core antibody/ae [Adverse Drug Reaction], hepatitis B core antibody/ct [Clinical Trial], hepatitis B core antibody/cm [Drug Comparison], hepatitis B core antibody/cr [Drug Concentration], hepatitis B core antibody/do [Drug Dose], hepatitis B core antibody/dt [Drug Therapy], hepatitis B core antibody/po [Oral Drug Administration], hepatitis B core antibody/pk [Pharmacokinetics], hepatitis B core antigen, hepatitis B surface antigen, hepatitis B(e) antigen, placebo, virus DNA, virus RNA, dysgeusia/si [Side Effect], presyncope/si [Side Effect], abdominal discomfort/si [Side Effect], abdominal distension/si [Side Effect], abdominal pain/si [Side Effect], adult, allergy/si [Side Effect], antiviral activity, area under the curve, article, asthenopia/si [Side Effect], backache/si [Side Effect], catheter infection/si [Side Effect], chronic hepatitis B/dt [Drug Therapy], chronic hepatitis B/si [Side Effect], clinical article, cohort analysis, conjunctivitis/si [Side Effect], constipation/si [Side Effect], controlled study, coughing/si [Side Effect], crackle/si [Side Effect], decreased appetite/si [Side Effect], dehydration/si [Side Effect], diarrhea/si [Side Effect], dizziness/si [Side Effect], drug dose comparison, drug dose increase, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29395
The Lancet Gastroenterology and Hepatology
LibKey Link

المؤلفون: Burge M., Segelov E., Tebbutt N.C., Reece W.H.H., Price T., Molloy M.P., Marx G., Jones K., Gibbs P., Feeney K., Clarke S.J.

مصطلحات الفهرس: intestine fistula/si [Side Effect], intestine perforation/si [Side Effect], large intestine perforation/si [Side Effect], lung embolism/si [Side Effect], major clinical study, male, metastatic colorectal cancer/dt [Drug Therapy], mucosa inflammation/si [Side Effect], multicenter study, multiple cycle treatment, nausea/si [Side Effect], neutropenia/si [Side Effect], neutrophil lymphocyte ratio, open study, overall survival, paresthesia/si [Side Effect], perianal abscess/si [Side Effect], peripheral neuropathy/si [Side Effect], phase 4 clinical trial, progression free survival, proteinuria/si [Side Effect], proteomics, rectum perforation/si [Side Effect], survival rate, treatment outcome, vomiting/si [Side Effect], bevacizumab/ae [Adverse Drug Reaction], bevacizumab/ct [Clinical Trial], bevacizumab/dt [Drug Therapy], capecitabine plus oxaliplatin/ct [Clinical Trial], capecitabine plus oxaliplatin/dt [Drug Therapy], proteome/ec [Endogenous Compound], capecitabine plus oxaliplatin/ae [Adverse Drug Reaction], abdominal pain/si [Side Effect], adult, aged, alopecia/si [Side Effect], anus fistula/si [Side Effect], article, cancer combination chemotherapy, cancer prognosis, carcinoma in situ/dt [Drug Therapy], constipation/si [Side Effect], controlled study, decreased appetite/si [Side Effect], diarrhea/si [Side Effect], digestive system perforation/si [Side Effect], drug safety, epistaxis/si [Side Effect], exploratory research, fatigue/si [Side Effect], female, gastroesophageal reflux/si [Side Effect], hand foot syndrome/si [Side Effect], human, hypertension/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29334
PLoS ONE
LibKey Link

المؤلفون: Palmer J., Lum C., Behren A., Tebbutt N.C., Cebon J., Carlino M.S., Klein O., Kee D., Nagrial A., Markman B., Underhill C., Michael M., Jackett L.

مصطلحات الفهرس: cancer patient, nivolumab/iv [Intravenous Drug Administration], nivolumab/pd [Pharmacology], nivolumab/pv [Special Situation for Pharmacovigilance], triacylglycerol lipase/ec [Endogenous Compound], abdominal pain/si [Side Effect], abnormally high substrate concentration in blood/si [Side Effect], adrenal insufficiency/si [Side Effect], adult, advanced cancer/dt [Drug Therapy], aged, anemia/si [Side Effect], antineoplastic activity, article, bile duct carcinoma/dt [Drug Therapy], cancer combination chemotherapy, cancer control, cancer immunotherapy, cancer regression, cancer survival, cancer tissue, clinical article, cohort analysis, colitis/si [Side Effect], controlled study, decreased appetite/si [Side Effect], diarrhea/si [Side Effect], drug efficacy, drug eruption/si [Side Effect], drug fatality/si [Side Effect], drug fever/si [Side Effect], drug safety, drug screening, drug withdrawal, endocrine disease/si [Side Effect], fatigue/si [Side Effect], female, gallbladder carcinoma/dt [Drug Therapy], hepatitis/si [Side Effect], human, human tissue, hyperthyroidism/si [Side Effect], hypertransaminasemia/si [Side Effect], hypophosphatemia/si [Side Effect], hypothyroidism/si [Side Effect], immunopathology/si [Side Effect], injection site reaction/si [Side Effect], kidney failure/si [Side Effect], lymphocytopenia/si [Side Effect], maintenance therapy, male, microsatellite instability, monotherapy, multicenter study, nausea/si [Side Effect], outcome assessment, overall survival, phase 2 clinical trial, pneumonia/si [Side Effect], progression free survival, prospective study, pruritus/si [Side Effect], response evaluation criteria in solid tumors, treatment duration, treatment response, triacylglycerol lipase blood level, very elderly, ipilimumab/ae [Adverse Drug Reaction], ipilimumab/ct [Clinical Trial], ipilimumab/cb [Drug Combination], ipilimumab/dt [Drug Therapy], ipilimumab/iv [Intravenous Drug Administration], ipilimumab/pd [Pharmacology], ipilimumab/pv [Special Situation for Pharmacovigilance], nivolumab/ae [Adverse Drug Reaction], nivolumab/ct [Clinical Trial], nivolumab/dt [Drug Therapy], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/29052
JAMA Oncology
LibKey Link

المؤلفون: Atkinson V., Haydon A., Millward M., Begbie S., Brown M., Markman B., Patterson W., Hill A., Horvath L., Nagrial A., Richardson G., Jackson C., Friedlander M., Parente P., Tran B., Wang L., Chen Y., Tang Z., Huang W., Wu J., Zeng D., Luo L., Solomon B., Desai J., Gan H., Barrow C., Jameson M.

مصطلحات الفهرس: endometrium cancer/di [Diagnosis], endometrium cancer/dt [Drug Therapy], endometrium cancer/et [Etiology], enzyme inhibition, fatigue/si [Side Effect], female, fever/si [Side Effect], gastroesophageal reflux/si [Side Effect], glossodynia/si [Side Effect], hand foot syndrome/si [Side Effect], headache/si [Side Effect], human, hyperkeratosis/si [Side Effect], hypertension/si [Side Effect], hypomagnesemia/si [Side Effect], hypophosphatemia/si [Side Effect], hypotension/si [Side Effect], insomnia/si [Side Effect], intestine obstruction/si [Side Effect], intestine perforation/si [Side Effect], lethargy/si [Side Effect], limb pain/si [Side Effect], major clinical study, male, maximum plasma concentration, maximum tolerated dose, melanoma/di [Diagnosis], melanoma/dt [Drug Therapy], melanoma/et [Etiology], multiple cycle treatment, muscle spasm/si [Side Effect], musculoskeletal chest pain/si [Side Effect], myalgia/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], non small cell lung cancer/di [Diagnosis], non small cell lung cancer/dt [Drug Therapy], non small cell lung cancer/et [Etiology], oncogene N ras, oropharynx pain/si [Side Effect], ovary cancer/di [Diagnosis], ovary cancer/dt [Drug Therapy], ovary cancer/et [Etiology], palmoplantar keratoderma/si [Side Effect], pericardial effusion/si [Side Effect], phase 1 clinical trial, photosensitivity/si [Side Effect], pleura effusion/si [Side Effect], positron emission tomography-computed tomography, priority journal, progression free survival, pruritus/si [Side Effect], QT prolongation/si [Side Effect], rash/si [Side Effect], sepsis/si [Side Effect], side effect/si [Side Effect], skin defect/si [Side Effect], skin hypertrophy/si [Side Effect], solid malignant neoplasm, thrombocytopenia/si [Side Effect], thrush/si [Side Effect], thyroid cancer/di [Diagnosis], thyroid cancer/dt [Drug Therapy], thyroid cancer/et [Etiology], thyroid papillary carcinoma/di [Diagnosis], thyroid papillary carcinoma/dt [Drug Therapy], thyroid papillary carcinoma/et [Etiology], treatment duration, upper abdominal pain/si [Side Effect], upper respiratory tract infection/si [Side Effect], urinary tract infection/si [Side Effect], vomiting/si [Side Effect], xerostomia/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], B Raf kinase/ec [Endogenous Compound], K ras protein/ec [Endogenous Compound], lifirafenib/ae [Adverse Drug Reaction], lifirafenib/ct [Clinical Trial], lifirafenib/cr [Drug Concentration], lifirafenib/do [Drug Dose], lifirafenib/dt [Drug Therapy], lifirafenib/to [Drug Toxicity], lifirafenib/pd [Pharmacology], dizziness/si [Side Effect], abdominal pain/si [Side Effect], adult, aged, alanine aminotransferase blood level, anemia/si [Side Effect], antineoplastic activity, arthralgia/si [Side Effect], article, backache/si [Side Effect], blood level, blood toxicity/si [Side Effect], body weight disorder/si [Side Effect], body weight loss, brain hemorrhage/si [Side Effect], cancer chemotherapy, cancer patient, cancer radiotherapy, cancer staging, cancer survival, chill/si [Side Effect], cohort analysis, colorectal cancer/di [Diagnosis], colorectal cancer/dt [Drug Therapy], colorectal cancer/et [Etiology], constipation/si [Side Effect], coughing/si [Side Effect], decreased appetite/si [Side Effect], dermatitis/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation/si [Side Effect], drug blood level, drug dose increase, drug half life, drug safety, drug tolerability, dry skin/si [Side Effect], dysgeusia/si [Side Effect], dysphonia/si [Side Effect], dyspnea/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28975
Journal of Clinical Oncology
LibKey Link

المؤلفون: Freeman J.L., Legge D., Huque M.H., Anderson M., Gillam L., Ong K.S., Carlin J.B., Fahey M., Scheffer I.E., Cranswick N., Slota-Kan S., Lilley B., Dirnbauer N.

مصطلحات الفهرس: anticonvulsive agent/dt [Drug Therapy], randomized controlled trial, cannabidiol/ct [Clinical Trial], cannabidiol/ae [Adverse Drug Reaction], anticonvulsive agent/pv [Special Situation for Pharmacovigilance], add on therapy, article, Bayes theorem, clinical decision making, clinical practice, clinical protocol, controlled study, convulsion/si [Side Effect], decreased appetite/si [Side Effect], diarrhea/si [Side Effect], double blind procedure, drug dose regimen, drug dose titration, drug efficacy, fatigue/si [Side Effect], fever/si [Side Effect], gastrointestinal symptom/si [Side Effect], human, intractable epilepsy/dt [Drug Therapy], intractable epilepsy/pc [Prevention], lethargy/si [Side Effect], outcome assessment, outpatient department, patient compliance, priority journal, cannabidiol/cb [Drug Combination], cannabidiol/cm [Drug Comparison], cannabidiol/do [Drug Dose], cannabidiol/dt [Drug Therapy], cannabidiol/po [Oral Drug Administration], cannabidiol/pv [Special Situation for Pharmacovigilance], placebo, valproic acid/ae [Adverse Drug Reaction], valproic acid/cb [Drug Combination], valproic acid/dt [Drug Therapy], valproic acid/pv [Special Situation for Pharmacovigilance], anticonvulsive agent/cb [Drug Combination], aminotransferase/ec [Endogenous Compound], vomiting/si [Side Effect], treatment planning, somnolence/si [Side Effect], side effect/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/28993
Journal of Paediatrics and Child Health
LibKey Link

المؤلفون: Qi Q., Chao Y., Hill A., Kang J., Wang L., Li K., Gan H., Wu Z., Yen C.-J., Markman B.

مصطلحات الفهرس: response evaluation criteria in solid tumors, treatment outcome, treatment response, upper respiratory tract infection/si [Side Effect], sorafenib/ae [Adverse Drug Reaction], sorafenib/ct [Clinical Trial], sorafenib/dt [Drug Therapy], tislelizumab/ae [Adverse Drug Reaction], tislelizumab/ct [Clinical Trial], tislelizumab/do [Drug Dose], tislelizumab/dt [Drug Therapy], human, advanced cancer/dt [Drug Therapy], antineoplastic activity, article, ascites/si [Side Effect], cancer control, clinical article, coughing/si [Side Effect], decreased appetite/si [Side Effect], drug dose escalation, drug eruption/si [Side Effect], drug fatality/si [Side Effect], drug safety, drug tolerability, fatigue/si [Side Effect], fever/si [Side Effect], liver cell carcinoma/dt [Drug Therapy], multicenter study, open study, phase 1 clinical trial, priority journal, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/38361
Annals of Oncology
LibKey Link

المؤلفون: Usmani S.Z., Oriol A., Karlin L., Cavo M., Rifkin R.M., Hayek F., Kirschner E., Bharany N., Overton L., Mannem S., Harroff A., Jain S., Roque T., McIntyre K., Yasencha C.K., Houck W., Schjesvold F., Yimer H.A., LeBlanc R., Takezako N., McCroskey R.D., Lim A.B.M., Suzuki K., Kosugi H., Grigoriadis G., Avivi I., Facon T., Jagannath S., Lonial S., Ghori R.U., Farooqui M.Z.H., Marinello P., San-Miguel J., Lim A., Walker T., Nicol A., Reece D., Elemary M., Boudreault Pedneault J.S., Attal M., Weisel K., Engelhardt M., Mackensen A., Quinn J., Cohen A., Magen-Nativ H., Benyamini N., Larocca A., Matsumoto M., Iida S., Ishikawa T., Kondo Y., Sunami K., Ando K., Teshima T., Chou T., Iwasaki H., Miki H., Matsumura I., Onishi Y., Izutsu K., Kizaki M., George A., Blacklock H., Simpson D., Waage A., Samoilova O., Nikitin E., Chagorova T., McDonald A., Patel M., Oriol Rocafiguera A., San Miguel Izquierdo J., Mateos M., Streetly M., Forsyth P., Jackson G., Jenkins S., Rifkin R., Yimer H., McCroskey R., Martincic D., Tarantolo S., Larson S., Faroun Y., Vaughn J., Baz R., Saylors G., Neppalli A., Raptis A., Fung H., Janosky M., Stevens D., Coleman M., Costa D., Cross S., Fanning S., Berges D.F., Harris T., Zackon I., Atanackovic D., Lee K., Oliff I., Lee W., Bensinger W., Lutzky J., Baron A.

مصطلحات الفهرس: pruritus/si [Side Effect], randomized controlled trial, rash/si [Side Effect], respiratory failure/si [Side Effect], rhabdomyolysis/si [Side Effect], sepsis/si [Side Effect], Stevens Johnson syndrome/si [Side Effect], survival analysis, systemic lupus erythematosus/si [Side Effect], toxic hepatitis/si [Side Effect], treatment duration, adrenal insufficiency/si [Side Effect], aged, anemia/si [Side Effect], article, backache/si [Side Effect], cardiopulmonary insufficiency/si [Side Effect], chromosome analysis, colitis/si [Side Effect], computer assisted tomography, constipation/si [Side Effect], controlled study, coughing/si [Side Effect], decreased appetite/si [Side Effect], dermatitis/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation/si [Side Effect], drug efficacy, drug eruption/si [Side Effect], drug safety, drug withdrawal, dry skin/si [Side Effect], dyspnea/si [Side Effect], erythema/si [Side Effect], erythema multiforme/si [Side Effect], fatigue/si [Side Effect], female, fever/si [Side Effect], Food and Drug Administration, health care quality, heart arrest/si [Side Effect], heart failure/si [Side Effect], human, hypersensitivity/si [Side Effect], hyperthyroidism/si [Side Effect], hypokalemia/si [Side Effect], hypothyroidism/si [Side Effect], infusion related reaction/si [Side Effect], insomnia/si [Side Effect], insulin dependent diabetes mellitus/si [Side Effect], intestine ischemia/si [Side Effect], intestine perforation/si [Side Effect], kidney failure/si [Side Effect], low drug dose, lung embolism/si [Side Effect], major clinical study, male, mortality rate, multicenter study, multiple myeloma/dt [Drug Therapy], myasthenia gravis/si [Side Effect], myocarditis/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], nuclear magnetic resonance imaging, open study, overall survival, pancreatitis/si [Side Effect], peripheral edema/si [Side Effect], phase 3 clinical trial, pneumonia/si [Side Effect], positron emission tomography, priority journal, progression free survival, quality of life assessment, upper gastrointestinal bleeding/si [Side Effect], upper respiratory tract infection/si [Side Effect], vomiting/si [Side Effect], dexamethasone/ae [Adverse Drug Reaction], dexamethasone/ct [Clinical Trial], dexamethasone/cb [Drug Combination], dexamethasone/dt [Drug Therapy], dexamethasone/po [Oral Drug Administration], dexamethasone/pv [Special Situation for Pharmacovigilance], lenalidomide/ae [Adverse Drug Reaction], lenalidomide/ct [Clinical Trial], lenalidomide/cb [Drug Combination], lenalidomide/dt [Drug Therapy], lenalidomide/po [Oral Drug Administration], lenalidomide/pv [Special Situation for Pharmacovigilance], pembrolizumab/ae [Adverse Drug Reaction], pembrolizumab/ct [Clinical Trial], pembrolizumab/cb [Drug Combination], pembrolizumab/dt [Drug Therapy], pembrolizumab/iv [Intravenous Drug Administration], pembrolizumab/pv [Special Situation for Pharmacovigilance], Article

URL: Click here for full text options
LibKey Link

المؤلفون: Usmani S.Z., Oriol A., Karlin L., Cavo M., Rifkin R.M., Hayek F., Kirschner E., Bharany N., Overton L., Mannem S., Harroff A., Jain S., Roque T., McIntyre K., Yasencha C.K., Houck W., Schjesvold F., Yimer H.A., LeBlanc R., Takezako N., McCroskey R.D., Lim A.B.M., Suzuki K., Kosugi H., Grigoriadis G., Avivi I., Facon T., Jagannath S., Lonial S., Ghori R.U., Farooqui M.Z.H., Marinello P., San-Miguel J., Lim A., Walker T., Nicol A., Reece D., Elemary M., Boudreault Pedneault J.S., Attal M., Weisel K., Engelhardt M., Mackensen A., Quinn J., Cohen A., Magen-Nativ H., Benyamini N., Larocca A., Matsumoto M., Iida S., Ishikawa T., Kondo Y., Sunami K., Ando K., Teshima T., Chou T., Iwasaki H., Miki H., Matsumura I., Onishi Y., Izutsu K., Kizaki M., George A., Blacklock H., Simpson D., Waage A., Samoilova O., Nikitin E., Chagorova T., McDonald A., Patel M., Oriol Rocafiguera A., San Miguel Izquierdo J., Mateos M., Streetly M., Forsyth P., Jackson G., Jenkins S., Rifkin R., Yimer H., McCroskey R., Martincic D., Tarantolo S., Larson S., Faroun Y., Vaughn J., Baz R., Saylors G., Neppalli A., Raptis A., Fung H., Janosky M., Stevens D., Coleman M., Costa D., Cross S., Fanning S., Berges D.F., Harris T., Zackon I., Atanackovic D., Lee K., Oliff I., Lee W., Bensinger W., Lutzky J., Baron A.

مصطلحات الفهرس: pruritus/si [Side Effect], randomized controlled trial, rash/si [Side Effect], respiratory failure/si [Side Effect], rhabdomyolysis/si [Side Effect], sepsis/si [Side Effect], Stevens Johnson syndrome/si [Side Effect], survival analysis, systemic lupus erythematosus/si [Side Effect], toxic hepatitis/si [Side Effect], treatment duration, adrenal insufficiency/si [Side Effect], aged, anemia/si [Side Effect], article, backache/si [Side Effect], cardiopulmonary insufficiency/si [Side Effect], chromosome analysis, colitis/si [Side Effect], computer assisted tomography, constipation/si [Side Effect], controlled study, coughing/si [Side Effect], decreased appetite/si [Side Effect], dermatitis/si [Side Effect], diarrhea/si [Side Effect], disease exacerbation/si [Side Effect], drug efficacy, drug eruption/si [Side Effect], drug safety, drug withdrawal, dry skin/si [Side Effect], dyspnea/si [Side Effect], erythema/si [Side Effect], erythema multiforme/si [Side Effect], fatigue/si [Side Effect], female, fever/si [Side Effect], Food and Drug Administration, health care quality, heart arrest/si [Side Effect], heart failure/si [Side Effect], human, hypersensitivity/si [Side Effect], hyperthyroidism/si [Side Effect], hypokalemia/si [Side Effect], hypothyroidism/si [Side Effect], infusion related reaction/si [Side Effect], insomnia/si [Side Effect], insulin dependent diabetes mellitus/si [Side Effect], intestine ischemia/si [Side Effect], intestine perforation/si [Side Effect], kidney failure/si [Side Effect], low drug dose, lung embolism/si [Side Effect], major clinical study, male, mortality rate, multicenter study, multiple myeloma/dt [Drug Therapy], myasthenia gravis/si [Side Effect], myocarditis/si [Side Effect], nausea/si [Side Effect], neutropenia/si [Side Effect], nuclear magnetic resonance imaging, open study, overall survival, pancreatitis/si [Side Effect], peripheral edema/si [Side Effect], phase 3 clinical trial, pneumonia/si [Side Effect], positron emission tomography, priority journal, progression free survival, quality of life assessment, upper gastrointestinal bleeding/si [Side Effect], upper respiratory tract infection/si [Side Effect], vomiting/si [Side Effect], dexamethasone/ae [Adverse Drug Reaction], dexamethasone/ct [Clinical Trial], dexamethasone/cb [Drug Combination], dexamethasone/dt [Drug Therapy], dexamethasone/po [Oral Drug Administration], dexamethasone/pv [Special Situation for Pharmacovigilance], lenalidomide/ae [Adverse Drug Reaction], lenalidomide/ct [Clinical Trial], lenalidomide/cb [Drug Combination], lenalidomide/dt [Drug Therapy], lenalidomide/po [Oral Drug Administration], lenalidomide/pv [Special Situation for Pharmacovigilance], pembrolizumab/ae [Adverse Drug Reaction], pembrolizumab/ct [Clinical Trial], pembrolizumab/cb [Drug Combination], pembrolizumab/dt [Drug Therapy], pembrolizumab/iv [Intravenous Drug Administration], pembrolizumab/pv [Special Situation for Pharmacovigilance], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/35895
LibKey Link

المؤلفون: Stagg R.J., Jameson M.B., Harris D.L., Kapoun A.M., Hughes B.G.M., Xu L., McKeage M.J., Kotasek D., Markman B., Hidalgo M., Millward M.J.

مصطلحات الفهرس: human, hypertension/si [Side Effect], male, maximum tolerated dose, multicenter study, multiple cycle treatment, nausea/si [Side Effect], neutropenia/si [Side Effect], New Zealand, non small cell lung cancer/dt [Drug Therapy], Notch signaling, open study, peripheral edema/si [Side Effect], pharmacodynamics, phase 1 clinical trial, priority journal, rash/si [Side Effect], side effect/si [Side Effect], Spain, thorax pain/si [Side Effect], thrombocytopenia/si [Side Effect], treatment response, vomiting/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], brain natriuretic peptide/ec [Endogenous Compound], carboplatin/ae [Adverse Drug Reaction], carboplatin/ct [Clinical Trial], carboplatin/cb [Drug Combination], carboplatin/dt [Drug Therapy], demcizumab/ae [Adverse Drug Reaction], demcizumab/ct [Clinical Trial], demcizumab/cb [Drug Combination], demcizumab/cr [Drug Concentration], demcizumab/do [Drug Dose], demcizumab/dt [Drug Therapy], demcizumab/pk [Pharmacokinetics], demcizumab/pd [Pharmacology], Notch receptor/ec [Endogenous Compound], pemetrexed/ae [Adverse Drug Reaction], pemetrexed/ct [Clinical Trial], pemetrexed/cb [Drug Combination], pemetrexed/dt [Drug Therapy], unclassified drug, delta like ligand 4/ec [Endogenous Compound], drug dose escalation, adult, aged, anemia/si [Side Effect], anxiety, area under the curve, article, Australia, cancer combination chemotherapy, cancer patient, clinical article, cohort analysis, constipation/si [Side Effect], decreased appetite/si [Side Effect], diarrhea/si [Side Effect], drug blood level, drug efficacy, drug safety, dysgeusia/si [Side Effect], dyspnea/si [Side Effect], fatigue/si [Side Effect], female, gene expression, headache/si [Side Effect], Article

URL: Targeted Oncology
Click here for full text options
LibKey Link

المؤلفون: Stagg R.J., Jameson M.B., Harris D.L., Kapoun A.M., Hughes B.G.M., Xu L., McKeage M.J., Kotasek D., Markman B., Hidalgo M., Millward M.J.

مصطلحات الفهرس: human, hypertension/si [Side Effect], male, maximum tolerated dose, multicenter study, multiple cycle treatment, nausea/si [Side Effect], neutropenia/si [Side Effect], New Zealand, non small cell lung cancer/dt [Drug Therapy], Notch signaling, open study, peripheral edema/si [Side Effect], pharmacodynamics, phase 1 clinical trial, priority journal, rash/si [Side Effect], side effect/si [Side Effect], Spain, thorax pain/si [Side Effect], thrombocytopenia/si [Side Effect], treatment response, vomiting/si [Side Effect], alanine aminotransferase/ec [Endogenous Compound], brain natriuretic peptide/ec [Endogenous Compound], carboplatin/ae [Adverse Drug Reaction], carboplatin/ct [Clinical Trial], carboplatin/cb [Drug Combination], carboplatin/dt [Drug Therapy], demcizumab/ae [Adverse Drug Reaction], demcizumab/ct [Clinical Trial], demcizumab/cb [Drug Combination], demcizumab/cr [Drug Concentration], demcizumab/do [Drug Dose], demcizumab/dt [Drug Therapy], demcizumab/pk [Pharmacokinetics], demcizumab/pd [Pharmacology], Notch receptor/ec [Endogenous Compound], pemetrexed/ae [Adverse Drug Reaction], pemetrexed/ct [Clinical Trial], pemetrexed/cb [Drug Combination], pemetrexed/dt [Drug Therapy], unclassified drug, delta like ligand 4/ec [Endogenous Compound], drug dose escalation, adult, aged, anemia/si [Side Effect], anxiety, area under the curve, article, Australia, cancer combination chemotherapy, cancer patient, clinical article, cohort analysis, constipation/si [Side Effect], decreased appetite/si [Side Effect], diarrhea/si [Side Effect], drug blood level, drug efficacy, drug safety, dysgeusia/si [Side Effect], dyspnea/si [Side Effect], fatigue/si [Side Effect], female, gene expression, headache/si [Side Effect], Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/37007
Targeted Oncology
Click here for full text options
LibKey Link

المؤلفون: Swanton C., Chitapanarux I., Ganju V., Im S.-A., Kim S.-B., Dechaphunkul A., Maneechavakajorn J., Spector N., Yau T., Afrit M., Ahmed S.B., Johnston S.R., Gibson N., Uttenreuther-Fischer M., Herrero J., Goh G., Schmid R., Guiver K., Arpornwirat W.

مصطلحات الفهرس: chromosomal instability, clinical article, computer assisted tomography, decreased appetite/si [Side Effect], dermatitis/si [Side Effect], disease course, drug dose reduction, dry eye/si [Side Effect], abdominal pain/si [Side Effect], acute diarrhea/si [Side Effect], adult, anemia/si [Side Effect], article, binding affinity, body weight disorder/si [Side Effect], brain metastasis, breast cancer/dt [Drug Therapy], bronchitis/si [Side Effect], dyspnea/si [Side Effect], epistaxis/si [Side Effect], erythema/si [Side Effect], evolutionary adaptation, fatigue/si [Side Effect], female, gastrointestinal disease, gene frequency, gene mutation, hand foot syndrome/si [Side Effect], histology, human, human tissue, male, middle aged, monotherapy, nausea and vomiting/si [Side Effect], neutropenia/si [Side Effect], nuclear magnetic resonance imaging, overall survival, paronychia/si [Side Effect], progression free survival, rash/si [Side Effect], sequence analysis, stomatitis/si [Side Effect], thrombocyte count, afatinib/ae [Adverse Drug Reaction], afatinib/ct [Clinical Trial], afatinib/cb [Drug Combination], afatinib/dt [Drug Therapy], afatinib/iv [Intravenous Drug Administration], epidermal growth factor receptor 2/ec [Endogenous Compound], navelbine/ae [Adverse Drug Reaction], navelbine/ct [Clinical Trial], navelbine/cb [Drug Combination], navelbine/dt [Drug Therapy], navelbine/iv [Intravenous Drug Administration], phosphatidylinositol 3, 4, 5 trisphosphate 3 phosphatase/ec [Endogenous Compound], trastuzumab, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/40460
PLoS Medicine
Click here for full text options
LibKey Link

المؤلفون: Swanton C., Chitapanarux I., Ganju V., Im S.-A., Kim S.-B., Dechaphunkul A., Maneechavakajorn J., Spector N., Yau T., Afrit M., Ahmed S.B., Johnston S.R., Gibson N., Uttenreuther-Fischer M., Herrero J., Goh G., Schmid R., Guiver K., Arpornwirat W.

مصطلحات الفهرس: chromosomal instability, clinical article, computer assisted tomography, decreased appetite/si [Side Effect], dermatitis/si [Side Effect], disease course, drug dose reduction, dry eye/si [Side Effect], abdominal pain/si [Side Effect], acute diarrhea/si [Side Effect], adult, anemia/si [Side Effect], article, binding affinity, body weight disorder/si [Side Effect], brain metastasis, breast cancer/dt [Drug Therapy], bronchitis/si [Side Effect], dyspnea/si [Side Effect], epistaxis/si [Side Effect], erythema/si [Side Effect], evolutionary adaptation, fatigue/si [Side Effect], female, gastrointestinal disease, gene frequency, gene mutation, hand foot syndrome/si [Side Effect], histology, human, human tissue, male, middle aged, monotherapy, nausea and vomiting/si [Side Effect], neutropenia/si [Side Effect], nuclear magnetic resonance imaging, overall survival, paronychia/si [Side Effect], progression free survival, rash/si [Side Effect], sequence analysis, stomatitis/si [Side Effect], thrombocyte count, afatinib/ae [Adverse Drug Reaction], afatinib/ct [Clinical Trial], afatinib/cb [Drug Combination], afatinib/dt [Drug Therapy], afatinib/iv [Intravenous Drug Administration], epidermal growth factor receptor 2/ec [Endogenous Compound], navelbine/ae [Adverse Drug Reaction], navelbine/ct [Clinical Trial], navelbine/cb [Drug Combination], navelbine/dt [Drug Therapy], navelbine/iv [Intravenous Drug Administration], phosphatidylinositol 3, 4, 5 trisphosphate 3 phosphatase/ec [Endogenous Compound], trastuzumab, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/40460
PLoS Medicine
Click here for full text options
LibKey Link

المؤلفون: Pianko S., Barnes E., Brainard D.M., Massetto B., Lin M., Han B., McHutchison J.G., Subramanian G.M., Cooper C., Agarwal K., George J., Nahass R.G., Forton D., Brown A., Foster G.R.

مصطلحات الفهرس: Hepatitis C virus genotype 3, human, insomnia/si [Side Effect], irritability, liver cirrhosis/dt [Drug Therapy], male, myalgia/si [Side Effect], nausea/si [Side Effect], North America, open study, pancreatitis/si [Side Effect], phase 3 clinical trial, priority journal, pruritus/si [Side Effect], randomized controlled trial, rash/si [Side Effect], side effect/si [Side Effect], thorax pain/si [Side Effect], thrombocyte count, treatment response, vomiting/si [Side Effect], hemoglobin, peginterferon alpha/ae [Adverse Drug Reaction], peginterferon alpha/cb [Drug Combination], peginterferon alpha/dt [Drug Therapy], peginterferon alpha/pd [Pharmacology], peginterferon alpha/sc [Subcutaneous Drug Administration], ribavirin/ae [Adverse Drug Reaction], ribavirin/cb [Drug Combination], ribavirin/dt [Drug Therapy], ribavirin/pd [Pharmacology], sofosbuvir/ae [Adverse Drug Reaction], sofosbuvir/cb [Drug Combination], sofosbuvir/dt [Drug Therapy], sofosbuvir/po [Oral Drug Administration], sofosbuvir/pd [Pharmacology], major clinical study, adult, arthralgia/si [Side Effect], article, atrial fibrillation/si [Side Effect], Australia and New Zealand, chill, controlled study, coughing/si [Side Effect], decreased appetite/si [Side Effect], depression/si [Side Effect], diarrhea/si [Side Effect], dizziness/si [Side Effect], drug efficacy, drug safety, drug substitution, drug withdrawal, dry skin/si [Side Effect], Europe, faintness/si [Side Effect], fatigue/si [Side Effect], female, fever/si [Side Effect], flu like syndrome/si [Side Effect], headache/si [Side Effect], hemoglobin blood level, hepatitis C/dt [Drug Therapy], Hepatitis C virus genotype 2, Article

URL: https://repository.monashhealth.org/monashhealthjspui/handle/1/40636
Gastroenterology
Click here for full text options
LibKey Link